Exelixis is a biotechnology company that develops differentiated pharmaceutical products to treat cancer and other serious diseases. Co. integrates high-throughput processes, medicinal chemistry, bioinformatics, structural...
Ohad Hammer submits: The pharmaceutical industry is in the midst of a severe innovation crisis, where more R&D money results in less approved drugs. In parallel, sales of most traditional blockbusters are being cannibalized by generic competition, forcing the big pharmas to exploit new concepts and rush new drug candidates...
SOUTH SAN FRANCISCO, Calif. -- Exelixis, Inc. (Nasdaq:EXEL) announced today that Frank Karbe, Executive Vice President and Chief Financial Officer of Exelixis, will present at the Thomas Weisel Partners 2008 Healthcare Conference at 10:20 a.m. ET/7:20 a.m. PT on Wednesday, September 3, 2008. Mr. Karbe will discuss updates to the...
SOUTH SAN FRANCISCO, Calif. -- Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the second quarter ended June 30, 2008. Revenues for the quarter ended June 30, 2008 were $30.4 million, compared to $29.3 million for the comparable period in 2007. The increase from 2007 to 2008 was...
SOUTH SAN FRANCISCO, Calif. -- Exelixis, Inc. (Nasdaq:EXEL) announced today that George A. Scangos, PhD, President and Chief Executive Officer of Exelixis, will present at the Bank of America 2008 Specialty Pharmaceuticals Conference at 9:30 a.m. ET/6:30 a.m. PT on Friday, August 8, 2008. Dr. Scangos will discuss updates to...
Data Report Submitted; Selection Decision Due in 90 Days SOUTH SAN FRANCISCO, Calif. -- Exelixis, Inc. (Nasdaq:EXEL) today announced that it has notified GlaxoSmithKline GSK that it has achieved proof-of-concept for XL184 under the collaboration agreement between GSK and Exelixis, and has submitted the corresponding data report to...
SAN FRANCISCO -- The biotech industry's report card for the first half of the year contains surprisingly good grades for its performance on the capital markets, and for partnering and venture capital deal making, but all other forms of financing didn't fare as well, particularly IPOs, the...
WESTBOROUGH, Mass. June 30 /PRNewswire/ -- Joseph B. Bolen, Ph.D., CSO of Millennium Pharmaceuticals, will chair the Focus on Cancer track IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics Conference and Exhibition taking place August 4-7 at the World Trade Center Boston & Seaport...
Exelixis Generated 10 IND Compounds and Received over $235 Million SOUTH SAN FRANCISCO, Calif., June 27 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that the company and GlaxoSmithKline, Inc. will bring their six-year collaboration to a successful conclusion on October 27, 2008, as...
SOUTH SAN FRANCISCO, Calif., June 18 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that Frank Karbe, executive vice president and chief financial officer at Exelixis, will present at the Piper Jaffray Europe Conference at 3:40 a.m. PT/6:40 a.m. ET/11:40 a.m. London, UK time on Wednesday, June...
NEW YORK, June 17 /PRNewswire/ -- Mergent, Inc., administrator for the HealthSharesTM Indexes, a series of 20 underlying indexes for the HealthSharesTM Exchange Traded Funds, today announced the quarterly rebalancing of the Indexes. The following securities will be added and deleted in the Indexes effective before...
Pivotal Trial in Medullary Thyroid Cancer Planned to Initiate This Summer SOUTH SAN FRANCISCO, Calif., June 16 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that the company and the U.S. Food and Drug Administration FDA have reached agreement on the phase 3 registration trial...
Compound Inhibits Mutant Forms of BCR-ABL That Cause Resistance to Current CML and ALL Therapies COPENHAGEN, Denmark, June 13 /PRNewswire-FirstCall/ -- Exelixis, Inc. today reported preliminary phase 1 data from an ongoing trial of XL228 in patients with chronic myelogenous leukemia CML or...
SOUTH SAN FRANCISCO, Calif., June 12 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that Frank Karbe, executive vice president and chief financial officer of Exelixis, will present at the William Blair & Company 28th Annual Growth Stock Conference at 1:10 p.m. PT/4:10 p.m. ET on Thursday,...
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c94179) has announced the addition of "Exelixis Inc: Premium Company Profile" to their offering. Introduction - Exelixis is a development-stage biotechnology company dedicated to the discovery and development of small molecule therapeutics for the treatment of cancer...
SOUTH SAN FRANCISCO, Calif., May 8 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that George A. Scangos, PhD, president and chief executive officer of Exelixis, will present at the Bank of America 2008 Health Care Conference at 11:40 a.m. ET/8:40 a.m. PT on Tuesday, May 13, 2008. Dr. Scangos...
SOUTH SAN FRANCISCO, Calif., May 6 /PRNewswire-FirstCall/ -- Exelixis, Inc. today reported financial results for the first quarter ended March 31, 2008. Revenues for the quarter ended March 31, 2008 were $27.9 million, compared to $28.1 million for the comparable period in 2007. Revenues for 2008...
FERF's Chapter Challenge Program was launched in honor of FEI's 75th Anniversary. The Chapter Challenge program encourages FEI chapters to make a leadership donation. Considering chapter size and treasury, FERF assembled a robust offering of contribution levels that included member benefits. Each level--Silver,...
Powerful, Dell is built to fit your business needs Customized systems, experts trained in small business, 24/7/365 support, and powerful, reliable technology. Dell, big results for small business.
Choose up to 5" more legroom with Economy Plus. Starting at $14.
Innovative USB Sleep'n Charge. Stylish Fusion™ finish. Ultra-portable. It's clear why the Satellite® U405 is a smart choice for you and your small business. Only from the laptop expert, Toshiba.
